Form 4: Upstream Bio Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director Erez Chimovits was granted 17,096 stock options in Upstream Bio, Inc. as part of standard compensation.
Summary
- Director Erez Chimovits received a grant of 17,096 stock options for Upstream Bio, Inc. (UPB) common stock.
- The options have an exercise price of $6.69 per share.
- The grant is subject to a vesting schedule tied to the earlier of June 9, 2027, or the next Annual Meeting of Stockholders.
- The reporting person is contractually obligated to transfer the economic benefits of these options to OrbiMed-affiliated entities.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The director does not retain the economic benefit of the options, as they are transferred to OrbiMed investment vehicles.
Risks
- Vesting is contingent upon the director's continued service to the company.
Future Outlook
The options vest in full on the earlier of June 9, 2027, or the date of the next Annual Meeting of Stockholders, provided the director remains in service.
Industry Context
StockSavvy.ai notes that equity grants to directors representing venture capital firms are standard practice in the biotechnology sector to align board incentives with corporate performance.
Comparison to Industry Standards
- The grant size and vesting terms are consistent with standard non-employee director compensation packages for mid-stage biotech companies.
Related Party Transactions
- The reporting person is obligated to transfer the economic benefit of the options to OrbiMed Advisors LLC and associated OrbiMed entities.
Stakeholder Impact
- Minimal impact on shareholders as this is a standard equity compensation grant.
Next Steps
- Vesting of options on June 9, 2027, or the next Annual Meeting of Stockholders.
Key Dates
| Date | Description |
|---|---|
| 06/09/2026 | Date of the option grant transaction. |
| 06/09/2027 | Vesting date for the stock options. |
| 06/08/2036 | Expiration date of the stock options. |
Keywords
Upstream Bio, UPB, Form 4, Insider Trading, Stock Options, OrbiMed, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.